Viva Ventures in the News
At Viva Ventures, we enjoy being part of innovative teams that are helping to change the world.
Please take a look at some of our partners and projects.
In this new deal Roche is putting up $125 million for an upfront and near-term milestones in a collaboration deal embedded with $1 billion in development goal money. Another $250 million is on the line for each new therapy that manages to make it all the way to an approval.
China’s Viva Biotech Holdings has applied for an IPO in Hong Kong to both fund their pursuit of promising upstarts and boost their manufacturing capabilities.
Viva Biotech is among key players operating in the protein expression market.
Viva Biotech is a Key Player in the Drug Discovery Service Market
Our Scientific Partners*
Pharmaceutical Business Review
Scientist: Zhixiong Ye, Ph.D.
Protein Science Journal
Scientist: Brian Hubbard, Ph.D.
Scientist: Cheney Mao, Ph.D.
*This is only a small selection of recent publications
Globe News Wire